Brief: Enrollment Completed In Phase 1 Influenza A Study With Cocrystal Pharma’S Oral Antiviral Candidate Cc-42344
26/10/2022 13:14
Oct 26 (Reuters) - Cocrystal Pharma Inc COCP.O :
* ENROLLMENT COMPLETED IN PHASE 1 INFLUENZA A STUDY WITH
COCRYSTAL
PHARMA’S ORAL ANTIVIRAL CANDIDATE CC-42344
* COCRYSTAL PHARMA INC SAYS PENDING APPROVAL BY AGENCY,
EXPECT
INITIATION OF PHASE 2A STUDY IN SECOND HALF OF 2023
Source text for Eikon: ID:nGNX6n2TjX
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway